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Structural
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Abstract
In 2018, the world of functional mitral regurgitation changed with the presentation of two trials – Multicentre Study of Percutaneous
Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes
Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials,
which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective
regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims
but very different findings.
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In patients with heart failure and reduced left ventricular ejection
fraction (LVEF), secondary (functional) mitral regurgitation, in which
the mitral valve leaflets and chordae are essentially normal, is the
result of functional and structural alterations of the left ventricle
(LV). Severe secondary mitral regurgitation (MR) is a predictor of
poor clinical outcomes in this patient population due to more
hospitalisations for heart failure (HF), poor quality of life and
shortened survival times.1–4 While guideline-directed medical therapy
(GDMT) may have an impact on LV function, symptomatology and
functional MR severity, there has been no data to show that surgical
treatment of secondary MR is associated with lower incidence of
death or hospitalisation.5
Percutaneous transcatheter treatment can be used to reduce MR
where the anterior and posterior mitral valve leaflets are approximated
with the MitraClip device (Abbott Vascular). In the Endovascular Valve
Edge-to-Edge Repair Study II (EVEREST II) trial, Feldman et al. showed
that although the MitraClip was safer than surgical mitral valve repair,
the transcatheter option was not as effective in reducing MR severity
among the study group, who mostly had primary MR.6 Prospective
clinical trials with hard clinical outcomes on the beneficial effect on
secondary MR of enhancing GDMT with percutaneous transcatheter
mitral valve repair had not been shown until now.7
At the 2018 Transcatheter Cardiovascular Therapies 30th Scientific
Session Conference, Gregg Stone presented the long-awaited and
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ground-breaking results of the Cardiovascular Outcomes Assessment
of the MitraClip Percutaneous Therapy for Heart Failure Patients
with Functional Mitral Regurgitation (COAPT) randomised prospective
clinical trial. COAPT showed that in more than 600 patients with heart
failure and severe functional MR, transcatheter percutaneous mitral
valve repair using the MitraClip device in conjunction with GDMT
when compared with GDMT alone, not only significantly reduced the
primary endpoint of heart failure rehospitalisations by 47%, but also
mortality at two years by 38%.7 Additionally, all 10 secondary endpoints
met statistical significance in favour of the MitraClip with GDMT over
GDMT alone. The reaction of the audience when the primary endpoint
results slide was displayed on the screen was enormous, with an
audible gasp followed by cheering and clapping. It had been difficult to
imagine the clinical outcome of the COAPT trial due to slow enrolment,
a lengthy time to complete, but mostly due to ominous predictions
in light of the outcomes from the Multicentre Study of Percutaneous
Mitral Valve Repair MitraClip Device in Patients With Severe Secondary
Mitral Regurgitation (MITRA-FR) clinical trial.
The COAPT trial results were clearly different from the negative results
of the MITRA-FR randomised prospective clinical trial presented by
Jean François Obadia a month earlier at the 2018 European Society of
Cardiology Congress.8 In the MITRA-FR trial, more than 300 HF patients
with severe MR were randomised to be treated with medical treatment
alone or with percutaneous transcatheter mitral valve repair (MitraClip)
along with medical therapy. All the participants were evaluated for a
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primary clinical endpoint at 12 months of a composite of death from
any cause or unplanned hospitalisation for HF.8 Dr Obadia discussed
the MITRA-FR trial’s negative primary outcome results at 12 months,
showing no significant difference in the rate of death or unplanned HF
hospitalisations in the intervention and control groups (54.6% versus
51.3%, OR 1.16, 95% CI [0.73 to 1.84], p=0.53).8
The big question was why there was such a significant difference in the
results between the MITRA-FR trial and the COAPT trial. Why was the
COAPT trial successful where the MITRA-FR trial seems to have failed?
There has been much debate about this issue in the cardiovascular
world since the two trials were presented.

A Tale of Two Trials
Recruitment
What is evident is that there were clear differences between the two
trials regarding patient selection, medical treatment optimisation,
the severity parameters of MR and the setting of the LV volume
index parameters. Some of this is due to differences between
European and American guidelines. In addition, these differences
were only found in a post-hoc analysis and are therefore subject to
inherent limitations.
Nevertheless, in the MITRA-FR trial, the majority of patients had an
average effective regurgitant orifice area (EROA) of 30 mm2 which
suggests moderate MR rather than severe, whereas in the COAPT
trial, the majority of patients had an average EROA of 40 mm2 which is
truly severe MR. The only COAPT subgroup that did not benefit from
MitraClip with GDMT was the patients who had an EROA <30 mm2
in setting of a dilated LV (>96 ml/m 2). A significant number of
patients (52%) with moderate MR (EROA <30 mm 2) were enrolled
in the MITRA-FR trial, whereas only 14% of patients with this
parameter were enrolled in the COAPT trial. This suggests that the
MitraClip procedure added to medical therapy optimisation does
not seem to have a significant beneficial effect on patients with
moderate MR and dilated LV cardiomyopathy.

to be more true to life in terms of medical therapy and optimisation.
The rates of drug use and medication titration throughout the MITRAFR trial course were not tracked, and although these were guideline
directed, they may not have been guideline optimised.
Yet the story does not end here – the percentage of drugs used in
MITRA-FR was higher than COAPT even if dose optimisation was not
checked by a selection committee. In addition, although there were
a significant number of HF hospitalisations in the COAPT trial, the
doses of medications were not changed significantly.

Size of Study and Study Design
The number of patients and follow-up were different between the two
trials. The MITRA-FR trial enrolled about 300 patients, 150 in each arm;
and the COAPT trial enrolled about 600, 300 in each arm. Perhaps
an effect size may not have been seen in MITRA-FR that was seen
in COAPT. Although hospitalisations differed early on between the
two patient groups in the COAPT trial (partly due to a more rigorous
medical arm), mortality did not differentiate until the second year. The
follow-up period for MITRA-FR was only 1 year. Perhaps the positive
nature of COAPT could be partially down to better design, probably due
to more accessible funding.

Technical Success and Procedural Safety
Technical success and procedural safety may be different between
the two trials. Residual MR class ≥3+ was higher post-clip for MITRAFR compared with COAPT, both acutely (9% versus 5%) and at 12
months (17% versus 5%); procedural complications – although low
and improving with current experience – were higher in MITRA-FR
than in COAPT (14.6% versus 8.5%), and residual MR class ≥3+ was
higher post-clip for MITRA-FR compared with COAPT, both acutely
(9% versus 5%) and at 12 months (17% versus 5%).7–8

The patient recruitment process was more selective in the COAPT
trial compared with the MITRA-FR trial, as indicated by the slow
enrolment and length of time of the trial. One review article
describes the difference as proportionate mitral regurgitation
(MITRA-FR) and disproportionate mitral regurgitation (COAPT) to the
degree of LV dilatation, with the COAPT trial enrolling patients with
EROA about 30% higher and LV volumes about 30% smaller than the
MITRA-FR trial.9

It is important to note that there was no common core lab evaluation
of both trials. More patients in COAPT had more than one clip
implanted compared with patients in the MITRA-FR trial. This raises
questions over the use of 3D imaging during the procedure. 3D
imaging is better than 2D imaging at identifying location of jets,
perpendicularity, post-clip leak and mitral valve area. For procedural
complications, there was about a twofold higher rate of device
implant failure, cardiogenic shock, stroke and tamponade in MITRAFR compared with COAPT, which may be due to different patient
populations or patients who are at different stages of the disease.
These are significant issues that are likely to be associated with
negative primary outcomes.

Medical Therapy and Optimisation

Selecting Patients Who Will Benefit From MitraClip

The ‘guideline-directed’ medical therapy used in the two trials
differed significantly. The COAPT patients were under more strict
evaluation with HF specialists overseeing the maximal doses
tolerated for all medications, before and at the time of the MitraClip
intervention. Several critiques of the COAPT trial have pointed out
that even at the highest enrolment centre, Cedars-Sinai Medical
Center in Los Angeles, with 46 enrolled patients total, that would
average about one study patient per month receiving the MitraClip
intervention. Only about 1–12% of patients had medication changes
during the trial.

Overall, how did the COAPT and MITRA-FR trials help in selecting the
most appropriate patient with secondary (functional) MR to receive
MitraClip therapy? The COAPT trial shows us that patients have to be
symptomatic, have substantial MR and have LV dysfunction (but not
too much dysfunction) and be on the highest tolerated doses of HF
medications. Patient selection, medical management and procedural
timing is key for success. This means that HF physicians will need
to be involved (and incentivised) members of the evaluation and
management team for mitral valve disease. Periprocedural imaging
and procedural technique needs to be optimised and patients with
only one clip should be evaluated closely. Patients with at least a
2-year expected lifespan after the procedure may do better from
a mortality standpoint, which should be part of the initial screening.

The highly stringent patient selectivity in the COAPT trial is the obvious
difference between the two trials. The MITRA-FR trial was designed
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Why Did COAPT Win While MITRA-FR Failed?
The Future
There are still some unanswered questions from these trials. Some
of these are based on COAPT subsets to better identify patients who
will benefit from the intervention, such as effects based on patients
with or without frailty, medical changes during the trial period,
postprocedural high gradient and more.
How do we improve the medical and procedural treatment for
those in MITRA-FR who are outside the range of COAPT? Will
other therapies,such as rings and valve replacement, provide better

1.

2.

3.

Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic
impact of functional mitral regurgitation in chronic heart
failure. Eur Heart J 2018;39:39–46. https://doi.org/10.1093/
eurheartj/ehx402; PMID: 29020337.
Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic
mitral regurgitation: long-term outcome and prognostic
implications with quantitative Doppler assessment.
Circulation 2001;103:1759–64. https://doi.org/10.1161/01.
CIR.103.13.1759; PMID: 11282907.
Rossi A, Dini FL, Faggiano P, et al. Independent prognostic
value of functional mitral regurgitation in patients with
heart failure. A quantitative analysis of 1256 patients with
ischaemic and non-ischaemic dilated cardiomyopathy. Heart
2011;97:1675–80. https://doi.org/10.1136/hrt.2011.225789;
PMID: 21807656.

INTERVENTIONAL CARDIOLOGY REVIEW

4.

5.

6.

outcomes, and for which patients? These are questions worthy of
consideration and we will undoubtedly see more data in the coming
years. At this time, both trials provide guidance we may use to get
maximal results in practice, and create opportunities for other mitral
valve therapies to also work in the COAPT and MITRA-FR patient
spaces. It is important to remember that MR and HF are a vast frontier
for us to explore and these two trials are just the beginning. We have
neither won nor lost at this time – we are still gathering information
about this important disease process, and our patients will look to us
for answers in the years ahead.
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